Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade

INTRODUCTION: It is unclear whether polymyalgia rheumatica (PMR) should be considered an inflammatory disease or an autoimmune disease. METHODS: Eighteen untreated early PMR patients and 18 sex- and age-matched healthy controls (HCs) were included. PMR patients received tocilizumab from week 0 to we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Ther
Main Authors: Carvajal Alegria, Guillermo, Cornec, Divi Y. K., Renaudineau, Yves, Saraux, Alain, Devauchelle-Pensec, Valérie
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7981388/
https://ncbi.nlm.nih.gov/pubmed/33745124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-021-00299-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados